Topic

Articles

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

Evonetix Receives Patent for Thermally-Controlled DNA Synthesis Technology

Mark White, PhD, is associate director, Biopharma Product Marketing, at Bio-Rad Laboratories.

Marwan Alsarraj is the Biopharma Segment manager at Bio-Rad.

Standardization is needed in CAR-T cell therapy development due to its inherent complexity.

Using ddPCR to Asses CAR-T Cell Quality

Mike Hennessy Jr. is the President and CEO of 

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Major League Moves

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Consumer advocates continue to press for initiatives to lower drug prices by revising or reducing patent protections.

Patent Rights Battles Escalate as Debate over Drug Costs and Access Drags On

Teva has reached an agreement with the Attorney General of Rhode Island to settle opioid-related claims.

Teva Reaches Agreement with Rhode Island to Settle Opioid-Related Claims

Emmes has acquired Casimir, marking its fourth major acquisition.

Emmes Acquires Rare-Disease CRO Casimir

The US Congress approved a federal spending package that increases funding for a range of programs to advance health and medicine.

Federal Budget Bill Boosts FDA Funding, Supports New Research Institute

Biotech companies and medical product manufacturers have condemned the invasion of Ukraine, while also looking to maintain supplies of essential medicines.

Ukraine Invasion Challenges Biopharma Research and Operations

Novartis will pay Voyager up to $1.75 billion for access to Voyager’s novel Tracer AAV capsids for potential use with three CNS targets.

Voyager Therapeutics Announces License Agreement with Novartis Worth Up to $1.75 Billion

A consortium of nine development partners will support Biovac's expansion of its existing vaccine manufacturing plant capacity, while Biovac itself aims to raise funds to boost increased vaccine manufacturing capacity across Africa.

Bio/Pharma Business